Interviews
View More
Waste in the Long Road to an IBD Cure

Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital and Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark.

High Costs of Specialty Pharmacy Make SDOH, Health Literacy Especially Relevant, Says Tiara Green, M.S.Ed. | Asembia's AXS25 Summit

High costs and the novelty and complexity of new therapies such as gene therapy present social determinants of health and health literacy challenges, says Tiara Green, president of Accessia Health

Accessia Health's Tiara Green, M.S.Ed., on Providing a Safety Net for Patients | Asembia's AXS25 Summit

Cost is a barrier to care for chronic and rare diseases, so financial assistance is way to lower that barrier and help people manage their health condition, says Green, president of Accessia Health

How the Move to Digital Pharmacy Addresses Brick and Mortar Closures | Asembia’s AXS25 Summit

Digital pharmacy solutions can help brick and mortar locations become more efficient, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.

Final Thoughts on Type 1 Diabetes: Innovations, Challenges and the Road Ahead

A panelist discusses how the adoption of C-peptide preservation as a critical end point in clinical trials represents a paradigm shift in type 1 diabetes (T1D) research, moving beyond glucose control alone to focus on disease-modifying therapies that can maintain endogenous insulin production and potentially alter the fundamental course of the disease.

Digital Solutions in Specialty Pharmacy Have Many Applications | Asembia’s AXS25 Summit

A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address affordability, access and industry collaboration, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.

More GLP-1s and Oral Options Could Shift the Weight Loss Drug Market | Asembia's AXS25 Summit

Becky Davis of Charles River Associates predicts that an influx of new and oral GLP-1 drugs, along with pricing pressures from policy and competition, will reshape the weight loss drug market in the next two years.

Access to GLP-1s for Weight Loss Depends on Employer Choices | Asembia's AXS25 Summit

At the 2024 Asembia Specialty Pharmacy Summit, Becky Davis, principal at Charles River Associates, discussed how employer-based insurance coverage for GLP-1s remains uneven—and what factors are influencing decisions about access to these weight-loss treatments.

Experts Weigh In on Future of IRA Policy Under Trump Administration | Asembia's AXS25 Summit

At this year’s Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive spoke with John Beardsley, senior vice president of corporate business development at CoverMyMeds, and Fauzea Husain, vice president of public policy at McKesson, about what potentially lies ahead for the Inflation Reduction Act under this Trump administration.

Official Media Partners